



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

<b>Reagent:</b>	H9 Cells
<b>Catalog Number:</b>	87
<b>Lot Number:</b>	070018
<b>Release Category:</b>	C
<b>Provided:</b>	1.1 x 10 <sup>7</sup> cells/ml. Viability is 96%.
<b>Cell Type:</b>	Single cell clone derived from a specific HUT 78 cell line, HT. HUT 78 is a human cutaneous T cell lymphoma derived from the peripheral blood of a patient with Sezary syndrome.
<b>Propagation Medium:</b>	RPMI 1640, supplemented with 2 mM L-glutamine and 50 µg/ml gentamicin, 90%; fetal bovine serum, 10%.
<b>Freeze Medium:</b>	RPMI 1640, 80%; fetal bovine serum, 10%; DMSO, 10%.
<b>Growth Characteristics:</b>	Maintain H9 cells at 1 x 10 <sup>5</sup> - 1 x 10 <sup>6</sup> cells/ml. Split 1:2-1:4 twice weekly. H9 grows as a single cell suspension with some clumping. Morphology is mature lymphocytic.
<b>Sterility:</b>	Negative for bacteria, fungi, and mycoplasma.
<b>Special Characteristics:</b>	This cell line was selected for high yield permissive growth with HIV-1.
<b>Recommended Storage:</b>	Liquid nitrogen.
<b>Contributor:</b>	Dr. Robert Gallo

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**References:**

Mann DL, O'Brien SJ, Gilbert DA, Reid Y, Popovic M, Read-Connole E, Gallo R, Gazdar A. Origin of the HIV-susceptible human CD4<sup>+</sup> cell line H9. *AIDS Res Hum Retroviruses* **5**:253-255, 1989.

Popovic M, Read-Connole E, Gallo RC. T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. *Lancet* **ii**:1472-1473, 1984.

Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. *Science* **224**:497-500, 1984.

**NOTE:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: H9 Cells from Dr. Robert Gallo." Also include the references cited above in any publications.

**The use of the H9 cell line and other neoplastic T cell lines to produce HIV-1 is described in U.S. Patent 4,520,113. .**

**Scientist at for-profit institutions or who intend commercial use of this reagent must contact Dr. Susan Ano, Office of Technology Transfer, National Institute of Health, 6011 Executive Blvd, Suite 325, Rockville, MD 20852, Tel:(301) 435-5515, Fax:(301) 402-0220, Email: [anos@mail.nih.gov](mailto:anos@mail.nih.gov), Website: <http://ott.od.nih.gov>, before the reagent can be released.**

**Last Updated**

November 02, 2015

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.